Table 1.
Ref. | Year | Fungus | Gender | Age | Joint | Charlson comorbidity index | Antifungal treatment | Surgical treatment | Treatment duration | Outcome | Follow-up in mo | Time from implantation to symptoms onset in mo | Time from symptoms onset to definite diagnosis by culture, in mo |
Koutserimpas et al[6] | 2018 | C. glabrata | Female | 68 | Knee | 4 | Anidulafungin / Voriconazole | TSRA | 28 wk | Successful | - | 180 | 0.5 |
Geng et al[7] | 2016 | C. glabrata | Male | 78 | Hip | 4 | Fluconazole / Amphotericin B / Caspofungin | Spacer implantation (failure)/RA | 26 wk | Successful | 11 | 34.8 | |
Klatte et al[8] | 2014 | C. glabrata | Female | 81 | Hip | 4 | Flucytosine / Amphotericin. B / Fluconazole | OSRA | - | Successful | 8 | - | |
Zhu et al[9] | 2014 | C. glabrata | Male | 44 | Hip | - | Amphotericin B / Voriconazole | No | 6 wk | Successful | 3 | - | 5 |
Anagnostakos et al[10] | 2012 | C. glabrata | Female | 51 | Hip | 6 | Fluconazole | TSRA | 6 wk | Successful | 70 | - | - |
Anagnostakos et al[10] | 2012 | C. glabrata | Male | 78 | Hip | 6 | Fluconazole | TSRA | 6 wk | Successful | 15 | - | - |
Bartalesi et al[11] | 2012 | C. glabrata | Female | 60 | Hip | - | Voriconazole / Caspofungin + Amphotericin B | TSRA | 6 wk | Successful | 48 | - | - |
Hall et al[12] | 2012 | C. glabrata | Female | 60 | Hip | 4 | Caspofungin | RA | 6 wk | - | - | < 0.5 | 0.2 |
Dumaine et al[13] | 2008 | C. glabrata | - | 72 | Knee | 5 | Caspofungin + Flucytosine / Fluconazole + Flucytosine | Arthrodesis | 16 wk | Successful | 15 | - | - |
Lejko-Zupanc et al[14] | 2005 | C. glabrata | Male | 74 | Hip | 5 | Amphotericin B + Fluconazole / Caspofungin | RA | → 3 wk | Successful | 36 | 72 | - |
Fabry et al[15] | 2005 | C. glabrata | Female | 74 | Knee | 6 | Voriconazole | 2x Debridement | 32 wk | Death from unrelated causes while on therapy | 24 | 72 | - |
Gaston et al[16] | 2004 | C. glabrata | Female | 42 | Knee | 4 | Voriconazole / Amphotericin B | Amputation (above knee) | 8 wk | Successful | 6 | 264 | - |
Açikgöz et al[17] | 2002 | C. glabrata | Female | 70 | Knee | - | Fluconazole | Arthrodesis | - | Successful | 7.5 | 9 | 6 |
Ramamohan et al[18] | 2001 | C. glabrata | Female | 65 | Hip | - | Amphotericin B + Flucytosine | TSRA | 7 wk | Successful | 24 | 48 | - |
Selmon et al[19] | 1998 | C. glabrata | Female | 75 | Knee | 5 | Amphotericin B/Itraconazole + Fluconazole | OSRA | > 8 wk | Successful | 48 | 84 | - |
Nayeri et al[20] | 1997 | C. glabrata | Female | 62 | Hip | 4 | Amphotericin B+ Flucytosine / Itraconazole + Flucytosine | OSRA | 11 wk | Successful | 22 | 60 | - |
Darouiche et al[21] | 1989 | C. glabrata | Female | 69 | Hip | - | Amphotericin B | RA | 1 wk | Successful | - | 27 | 0.5 |
Goodman et al[22] | 1983 | C. glabrata | Female | 69 | Hip | 3 | - | RA | - | Successful | 12 | 27 | - |
Geng et al[7] | 2016 | C. papapsilosis | Male | 67 | Knee | 3 | Fluconazole | TSRA | 10 wk | Successful | 48 | 3 | - |
Wang et al[23] | 2015 | C. parapsilosis | Female | 67 | Knee | 4 | Fluconazole | TSRA | 10 wk | Successful | 27 | - | - |
Wang et al[23] | 2015 | C. parapsilosis | Male | 74 | Knee | 5 | Fluconazole | TSRA | 8 wk | Successful | 30 | - | - |
Wang et al[23] | 2015 | C. pasapsilosis | Female | 71 | Knee | 4 | Fluconazole | TSRA | 6 wk | Successful | 62 | - | - |
Klatte et al[8] | 2014 | C. parapsilosis | Male | 69 | Knee | 8 | Flucytosine+ Amphotericin. B | OSRAx3 (Failure the first 2 times) | - | Successful | 19 | 1 | - |
Klatte et al[8] | 2014 | C. parapsilosis | Female | 82 | Knee | 4 | Flucytosine+ Amphotericin. B | OSRA | - | Successful | 2 | - | |
Klatte et al[8] | 2014 | C. parapsilosis | Male | 46 | Knee | 1 | Flucytosine+ Amphotericin. B | OSRA | - | Successful | 6 | - | |
Ueng et al[24] | 2013 | C. parapsilosis | Male | 62 | Knee | 4 | Fluconazole | TSRA | - | Successful | ≥ 24 | 4.5 | 1.5 |
Ueng et al[24] | 2013 | C. parapsilosis | Male | 77 | Knee | - | Fluconazole | TSRA | - | Successful | ≥ 24 | 4 | 3 |
Ueng et al[24] | 2013 | C. parapsilosis | Male | 66 | Hip | - | Fluconazole | TSRA | - | Successful | ≥ 24 | 2 | 1 |
Ueng et al[24] | 2013 | C. parapsilosis | Male | 76 | Knee | 8 | Fluconazole | TSRA | - | Successful | ≥ 24 | 33 | 2 |
Ueng et al[24] | 2013 | C. parapsilosis | Male | 36 | Knee | - | Fluconazole | TSRA | - | Successful | ≥ 24 | 74 | 2 |
Ueng et al[24] | 2013 | C. parapsilosis | Male | 66 | Hip | 4 | Fluconazole | RA | - | - | - | 2 | 2 |
Kuiper et al[25] | 2013 | C. parapsilosis | Male | 58 | Hip | - | None | RA/refused further treatment | - | Refused further treatment | 8 | - | - |
Chiu et al[26] | 2013 | C. parapsilosis | Male | 71 | Hip | 5 | Fluconazole | RA | 40 wk | Successful | 24 | 48 | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 71 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 46 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 76 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 56 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 76 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 67 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 72 | Knee | - | Fluconazole, | TSRA | ≥ 6 wk | Successful | 73 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female1 | 611 | Bilateral Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 65 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female1 | 611 | Bilateral Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 46 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 67 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 65 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 68 | Knee | - | Fluconazole, | TSRA | ≥ 6 wk | Successful | 69 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 68 | Knee | - | Fluconazole, | TSRA | ≥ 6 wk | Successful | 42 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 67 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 49 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 60 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 41 | - | - |
Hwang et al[4] | 2012 | C. parapsilosis | Female | 73 | Knee | - | Amphotericin B / Fluconazole | TSRA | ≥ 6 wk | Successful | 52 | - | - |
Anagnostakos et al[10] | 2012 | C. parapsilosis | Male | 67 | Knee | - | Fluconazole | RA | 6 wk | - | - | - | - |
Dutronc et al[27] | 2010 | C. parapsilosis | Male | 66 | Hip | 5 | Fluconazole | TSRA | 24 wk | Successful | - | 0 | - |
Dutronc et al[27] | 2010 | C. parapsilosis | Female | 77 | Hip | 4 | Ampotericin B + fluorocytosine / Fluconazole | RA | 38 wk | Successful | - | 5 | - |
Antony et al[28] | 2008 | C. parapsilosis | Female | 67 | Shoulder | 3 | Voriconazole / Fluconazole | TSRA | - | Successful | 6 | - | - |
Antony et al[28] | 2008 | C. parapsilosis | Female | 67 | Hip | 3 | Fluconazole | TSRA | - | Successful | - | - | - |
Yang et al[29] | 2001 | C. parapsilosis | Female | 68 | Knee | 3 | Fluconazole | TSRA | 10 wk | Successful | 48 | 0 | 16 |
Bruce et al[30] | 2001 | C. parapsilosis | Female | 51 | Hip | - | Fluconazole | TSRA | - | Successful | 84 | 36 | 36 |
Brooks[31] | 1998 | C. parapsilosis | Male | 64 | Knee | 5 | Amphotericin B/Fluconazole | Debridement | 28 wk | Successful | 24 | 15 | 4 |
Wada et al[32] | 1998 | C. parapsilosis | Male | 77 | Knee | 4 | Fluconazole | Debridement | 28 wk | Successful | 36 | 0.5 | 0.5 |
Cushing et al[33] | 1997 | C. parapsilosis | Female | 73 | Knee | - | Fluconazole | No | > 24 wk | Successful | 12 | 1 | - |
Fukasawa et al[34] | 1997 | C. parapsilosis | Female | 80 | Knee | - | Fluconazole | Debridement | 53 wk | Successful | 24 | 2 | |
White et al[35] | 1995 | C. parapsilosis | Female | 64 | Knee | - | Fluconazole/Ampotericin B / Itraconazole | RA | 20 wk | Successful | - | 0 | 9 |
Tunkel et al[36] | 1993 | C. parapsilosis | Male | 37 | Knee | 6 | Amphotericin B / Ketoconazole / Fluconazole | TSRA (Failure)/Amputation (Successful) | - | Successful | 7 | 4 | 0 |
Paul et al[37] | 1992 | C. pasapsilosis | Male | 63 | Knee | - | Amphotericin + fluorocytosine / ketoconazole | Arthrodesis | 9 wk | Successful | 24 | 3 | 4 |
Lim et al[38] | 1986 | C. parapsilosis | Male | 35 | Knee | - | Fluorocytosine | Arthrodesis | - | - | - | 0 | 6 |
Younkin et al[39] | 1984 | C. parapsilosis | Female | 75 | Hip | - | Fluorocytosine+ Amphotericin B | TSRA | 6 wk | Successful | 24 | 0 | 60 |
Lichtman[40] | 1983 | C. parapsilosis | Male | 59 | Shoulder | - | Amphotericin B / ketoconazole | RA | Indefinite (> 58 d) | -- | - | 20 | 9 |
MacGregor et al[41] | 1979 | C. parapsilosis | Male | 64 | Knee | - | Amphotericin B + Fluorocytosine | Non-surgical (failure)/ then RA | 21 wk | Successful | 12 | 27 | 5 |
Sebastian et al[42] | 2017 | C. tropicalis | Male | 53 | Hip | 3 | Fluconazole | TSRA | 28 wk | Successful | NR | 24 | 0 |
Reddy et al[43] | 2013 | C. tropicalis | Female | 62 | Knee | 3 | Fluconazole | TSRA | 30 wk | Successful | 24 | 22.5 | 1.5 |
Ueng et al[24] | 2013 | C. tropicalis | Male | 67 | Hip | - | Fluconazole | RA | - | - | - | 15 | 1 |
Lidder et al[44] | 2013 | C. tropicalis | Female | 76 | Hip | - | Amphotericin B | RA | 24 wk | Successful | 24 | 36 | 15 |
Azam et al[45] | 2008 | C. tropicalis | Male | 73 | Hip | 6 | Caspofungin / Fluconazole | TSRA | ≥ 9 wk, (Caspofungin 1 wk, fluconazole ≥ 8 wk) | Successful | 12 | 108 | - |
Wyman et al[46] | 2002 | C. tropicalis | Male | 62 | Knee | Fluconazole / Amphotericin B | TSRA | 18 wk | Successful | 36 | 0.25 | 6 | |
Darouiche et al[21] | 1989 | C. tropicalis | Male | 72 | Hip | 4 | Amphotericin B / ketoconazole | Debridement (failure)/ RA | 12 wk | Successful | 36 | 0.5 | 1 |
Lambertus et al[47] | 1988 | C. tropicalis | Male | 61 | Hip | 3 | Amphotericin B | RA | - | Successful | 24 | 6 | 6 |
Lambertus et al[47] | 1988 | C. tropicalis | Male | 65 | Hip | - | Amphotericin B / ketoconazole | RA/ arthrodesis | >24 wk | Successful | 14 | 4 | 4 |
73.Goodman et al[30] | 1983 | C. tropicalis | Female | 59 | Knee | - | Amphotericin B | TSRA (failure)/ RA | 6 wk | Successful | 12 | 3 | 6 |
Hwang et al[4] | 2012 | C. pelliculosa | Female | 67 | Knee | - | Fluconazole | TSRA | ≥ 6 wk | Successful | 56 | - | - |
Hwang et al[4] | 2012 | C .pelliculosa | Female | 64 | Knee | - | Amphotericin B / fluconazole | TSRA | ≥ 6 wk | Successful | 35 | - | - |
Hwang et al[4] | 2012 | C. pelliculosa | Male | 75 | Knee | - | Amphotericin B / fluconazole | TSRA | ≥ 6 wk | Successful | 34 | - | - |
Klatte et al[8] | 2014 | C. lusitaniae | Male | 74 | Knee | 6 | Voriconazole | OSRA | - | Successful | 12 | - | |
Hwang et al[4] | 2012 | C. lusitaniae | Female | 66 | Knee | - | Amphotericin B / fluconazole | TSRA | ≥ 6 wk | Successful | 43 | - | - |
Hwang et al[4] | 2012 | C. famata | Female | 83 | Knee | - | Amphotericin B / fluconazole | TSRA | ≥ 6 wk | Successful | 33 | - | - |
Anagnostakos et al[10] | 2012 | C. lipolytica | Male | 77 | Hip | 7 | Fluconazole | TSRA | 6 wk | Successful | 22 | - | - |
Wang et al[23] | 2015 | C. utilis | Female | 56 | Knee | 2 | Fluconazole | TSRA | 6 wk | Successful | 24 | - | 5 |
Dutronc et al[27] | 2010 | C. guillermondii | Male | 76 | Knee | 4 | Amphotericin B+ fluorocytosine / Fluconazole | None | 14 wk (2 wk AMB+5FC, then 3 mo FZ) | Failure | - | 0 | - |
Geng et al[7] | 2016 | C. freyschussii | Female | 58 | Knee | 2 | Fluconazole / Caspofungin | TSRA | 10 wk | Successful | 55 | <0.25 |
Patient demographics, antifungal treatment, its duration, as well as infection outcome and follow-up period are presented.
Bilateral PJI in the same patient; -: Not reported or unclear. TSRA: Two stage revision arthroplasty; OSRA: One stage revision arthroplasty; RA: Resection arthroplasty.